Home Tags Daiichi Sankyo

Tag: Daiichi Sankyo

Trastuzumab deruxtecan Doubles Progression-Free Survival in Metastatic Breast Cancer with Low...

The use of trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival (PFS) compared to standard-of-care treatment with...

The Rise of HER2-targeting ADCs and the Journey from Breakthrough Therapy...

Antibody-drug conjugates (ADCs) as precision targeted cancer therapies have started to deliver on their early promise as an innovative novel drug modality as demonstrated...

First patient Dosed with Trastuzumab Deruxtecan in DESTINY-Breast09 Head-to-Head HER2+ mBC...

A first patient was dosed in DESTINY-Breast09 (NCT04784715), a global head-to-head Phase 3 clinical trial evaluating the safety and efficacy of trastuzumab deruxtecan (Enhertu®;...

Patritumab Deruxtecan Shows Tumor Response Across Multiple Resistance Mechanisms in Patients...

New data presented at this year’s annual meeting of the American Society of Clinical Oncology, held online June 4 - 8, 2021, confirms promising...

Daiichi Sankyo Reaffirms Long-term Goals with Increased Investment in ADCs

With the launch of fam-trastuzumab-deruxtecan-nxki (Enhertu®), Daiichi Sankyo's first antibody-drug conjugates, coupled with a strong pipeline of innovative ADC, the company has established a...

José Baselga, a Leading Cancer Researcher, Dies at 61

José Baselga, MD, Ph.D., an internationally renowned expert in the development of molecular targeted agents, the R&D chief at AstraZeneca, who had earlier been...

Daiichi Sankyo: Realigning for Agility

Daiichi Sankyo first approached me in 2015 with a potential opportunity in global oncology development, and I listened carefully as they explained how they...

First Patients Dosed in Phase II Study of Patritumab Deruxtecan in...

A first patient was doses in a phase II clinical trial designed to evaluate patritumab deruxtecan (previously known as U3-1402), a HER3 directed DXd...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2020: Late-Breaking Data for HER3 Directed ADC Patritumab Deruxtecan in...

Data for patritumab deruxtecan (U3-1402; Daiichi Sankyo) and fam-trastuzumab deruxtecan-nxki* (Enhertu®; Daiichi Sankyo/AstraZeneca), two antibody-drug conjugates (ADC) based on Daiichi Sankyo's proprietary DXd ADC...
Featured Image: Women and the power to fight breast cancer Courtesy: © 2017. Fotolia. Used with permission.

Daiichi Sankyo and Gustave Roussy Sign Multi-year and Multi-study Adaptive Phase...

Daiichi Sankyo and Gustave Roussy have signed a multi-year, multi-study research collaboration for the ongoing development of DS-1062 and patritumab deruxtecan (previously known as U3-1402),...

X